Navigation Links
Viral Therapy Slows Pediatric Tumors in Mice
Date:2/15/2008

Treatment leaves healthy tissue unharmed while targeting solid masses, study finds

FRIDAY, Feb. 15 (HealthDay News) -- A laboratory-engineered virus can successfully slow the growth of two types of hard-to-treat pediatric tumors without harming healthy tissue, a new study shows.

The targeted viral therapy, dubbed rQT3, slowed neuroblastoma and peripheral nerve sheath tumors in mice, according to findings published in the Feb. 15 issue of Cancer Research. It also resulted in longer life spans in the mice compared with ones receiving just saline or other treatments for the tumors.

Neuroblastoma is the most common solid cancer tumor in childhood, most often striking those under age 5. Malignant peripheral nerve sheath tumors affect the connective tissue surrounding nerves.

Researchers at Cincinnati Children's Hospital Medical Center armed the oncolytic herpes simplex virus (oHSV)with a gene that steps up the body's work to block enzymes that aid the development and progression of certain cancers. Previous studies had shown oHSV can infect and kill human cancer cells without causing other harm or disease.

"Malignant solid tumors are still very difficult to treat effectively, especially without causing harm to normal tissues, so we need to find innovative therapeutic approaches," Dr. Timothy Cripe, a physician and researcher at Cincinnati Children's Hospital Medical Center, said in a prepared statement. "In our study, this tumor-targeting viral therapy enhanced anti-tumor activity by stimulating multiple biological processes, including directly killing the cancer cells and reducing the formation of blood vessels that fed the tumors. These data support continuing development and study of our tumor-targeted viral therapy to fight cancer."

The gene added to the virus carries instructions for a cancer-fighting protein, human tissue inhibitor of metalloproteinase 3 (TIMP3). TIMP3 blocks enzymes that aid the development and progression of cancer, called matrix of metalloproteinases (MMP).

MMPs help break down molecules that are important for the structural support and normal development of cells, organs and maintenance of tissues. However, when MMP activity becomes unbalanced, the enzyme plays a well-documented role in the formation of invasive and metastatic cancers, including pediatric neuroblastoma.

More information

The National Cancer Institute has more about childhood cancers.



-- Kevin McKeever



SOURCE: Cincinnati Children's Hospital Medical Center, news release, Feb. 15, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients
2. IPM Reaches Landmark Agreement with Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide
3. Antiretroviral Drugs May Prevent Vaginal Transmission of HIV
4. MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study
5. Antivirals reduce deaths from flu in hospitalized patients
6. American Medical Association Clears Path for Adenoviral Conjunctivitis - Pink Eye - Detector
7. Is it pancreatitis in acute abdominal pain in acute viral hepatitis?
8. Mayo Clinic Proceedings article explores possible link between obesity and viral infections
9. Antiviral Wont Improve Bells Palsy Outcome
10. Key Viral Change Could Help Bird Flu Spread
11. DNA damage response confers a barrier for viral tumorigenesis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Viral Therapy Slows Pediatric Tumors in Mice
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield of ... rating of “A” and its outlook as “stable.” At the same time, the ratings ... fallen in recent years, dip below “capital adequacy” thresholds required for its strong rating. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio ... These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most ... disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), a ... and delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts ... hospital and decide to donate. , “Women’s Hospital at Renaissance has been a ...
(Date:4/28/2017)... ... 28, 2017 , ... Bill Howe started his sewer and drain company in ... Howe joined the team, the Bill Howe brand was born and they began cultivating ... giving back to the San Diego community in which they worked, lived and were ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... assisting the Brooke Grove Foundation implement a Microsoft Dynamics GP solution that integrates ... leading ERP expert that specializes in long-term care, Brooke Grove now has the ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- Vivify Health, the pioneer and market leader of remote ... significant patent for the advancement of healthcare delivery from ... health.  This landmark patent provides the company with broad ... position as the leader in remote care.  ... to apply consumer mobile devices, wireless biometrics, EMR integration ...
(Date:4/20/2017)... 20, 2017 Research and Markets has announced ... Driven by Rapidly Expanding Injectables Market and Increasing Usage of Complex ... ... technologies will rise from USD 20 Billion in 2015 to around ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ...
(Date:4/20/2017)... April 20, 2017 Research and Markets ... Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key ... to their offering. ... global pharmacogenomics market was valued at US$ 7,167.6 Mn in ... 2024, expanding at a CAGR of 5.6% from 2016 to ...
Breaking Medicine Technology: